Sonoma Pharmaceuticals (SNOA) Operating Income (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Operating Income of -$351000.0 for Q1 2026, up 46.49% year-over-year from -$239600.4 in Q1 2025, and up 48.23% quarter-over-quarter from -$678000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Operating Income (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Operating Income history runs 17 years deep, the most recent figure standing at -$351000.0 for Q1 2026.
- In Q1 2026, Operating Income rose 46.49% year-over-year to -$351000.0; the TTM figure through Mar 2026 stood at -$2.5 million (up 33.67% YoY), while the FY2026 annual figure was -$2.5 million, up 33.67% from the prior year.
- Operating Income for Q1 2026 stood at -$351000.0, up from -$678000.0 in the prior quarter.
- The five-year high for Operating Income was -$337000.0 in Q3 2025, with the low at -$3.1 million in Q1 2022.
- The 5-year median for Operating Income is -$1.0 million (2024), against an average of -$1.1 million.
- The sharpest annual moves came in 2022 and 2023: Operating Income tumbled 91.44% in 2022, then soared 62.52% in 2023.
- Sonoma Pharmaceuticals' Operating Income stood at -$1.8 million in 2022, then soared by 53.98% to -$844000.0 in 2023, then retreated by 22.16% to -$1.0 million in 2024, then soared by 34.24% to -$678000.0 in 2025, then soared by 48.23% to -$351000.0 in 2026.
- Business Quant data shows SNOA's Operating Income at -$351000.0 in Q1 2026, -$678000.0 in Q4 2025, and -$337000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.19 Mn | -145,899.91 | 2.58 Mn | -40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40,000.00 |
| Mar 31, 2026 | -351,000.00 |
| Dec 31, 2025 | -678,000.00 |
| Sep 30, 2025 | -337,000.00 |
| Jun 30, 2025 | -1.10 Mn |
| Mar 31, 2025 | -656,000.00 |
| Dec 31, 2024 | -1.03 Mn |
| Sep 30, 2024 | -850,000.00 |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | -844,000.00 |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Mar 31, 2023 | -1.15 Mn |
| Dec 31, 2022 | -1.83 Mn |
| Sep 30, 2022 | -731,000.00 |
| Jun 30, 2022 | -855,000.00 |
| Mar 31, 2022 | -3.06 Mn |
| Dec 31, 2021 | -958,000.00 |
| Sep 30, 2021 | -964,000.00 |